K_V11.1 (hERG1)-centered macromolecular membrane complexes regulate proliferation in B cell lymphomas and constitute...

Area of Science:

• Molecular biology and immunology
• Cancer research
• Ion channel function

Background:

• Potassium (K+) channel activity is crucial for T and B lymphocyte activation.
• K+ channel expression is altered in cancer, influencing neoplastic progression.
• Diffuse large B cell lymphoma (DLBCL) exhibits altered K+ channel profiles.

Purpose of the Study:

• To investigate K+ channel expression in DLBCL cell lines and EBV-infected lymphocytes.
• To identify specific K+ channels involved in lymphoma cell proliferation.
• To explore the therapeutic potential of targeting the hERG1-β1 integrin complex.

Main Methods:

• Functional expression analysis of K+ channels (K_V1.3, K_Ca3.1, K_V11.1/hERG1, K_V12.2/hELK2) in DLBCL cell lines.
• Investigation of the hERG1-β1 integrin complex formation upon cell adhesion to fibronectin.
• Assessment of proliferation reduction by disrupting the hERG1-β1 complex using a bispecific antibody and clarithromycin.
• Clinical correlation analysis in MALT lymphoma patients treated with clarithromycin.

Main Results:

• DLBCL cells express K_V1.3, K_Ca3.1, hERG1, and hELK2 channels.
• hERG1 and K_Ca3.1 channels tend to be substituted by EAG channels, particularly hERG1, in DLBCL compared to normal lymphocytes.
• Cell adhesion stimulates the formation of a cancer-specific hERG1-β1 integrin complex in DLBCL.
• Disruption of the hERG1-β1 complex significantly reduced lymphoma proliferation.
• A trend towards improved survival was observed in MALT lymphoma patients expressing the hERG1-β1 complex treated with clarithromycin.

Conclusions:

• The hERG1-β1 integrin complex plays a role in promoting lymphoma cell proliferation.
• Targeting the hERG1-β1 integrin complex represents a potential novel therapeutic strategy for lymphomas.
• Clarithromycin demonstrates potential as a therapeutic agent by disrupting this complex.